3040 POSTER Optimal dose for an every 2 week (q2w) cetuximab (C) regimen in patients (pts) with metastatic colorectal cancer (mCRC): a phase I safety, pharmacokinetics (PK) and pharmacodynamics (PD) study of weekly (q1w) and q2w schedules

Ciardiello, Fortunato; Vega-Villegas, M. E.; Casado, Esther; Rodríguez-Braun, Edith; Martinelli, Erika; Rojo, F.; Baselga, J.; Kisker, Oliver; Tabernero, Josep

doi:10.1016/s1359-6349(07)70968-0

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, cetuximab administered q2w in combination with irinotecan is an option that is as active and safe as the standard q1w regimen, confirming the results of previous studies [10][11][12] .…”

Section: Discussionsupporting

confidence: 89%

“…This information was not provided during the development of this trial. Nonetheless, our final results (efficacy and safety of cetuximab q2w) are similar to other studies with cetuximab given q2w where K-ras status was not performed [11,12] .…”

Section: Discussionsupporting

confidence: 87%

“…Preliminary findings indicate that q2w administration of cetuximab (500 mg/m 2 ) may be a potentially convenient alternative to the approved weekly dosing regimen of 250 mg/m 2 (following an initial dose of 400 mg/ m 2 ) in the treatment of mCRC [10] . Cetuximab q1w and q2w have shown similar pharmacokinetic, pharmacodynamic and safety results [11,12] . Additionally, the efficacy of the q2w regimen has also been confirmed in previous studies [13][14][15] .…”

mentioning

confidence: 99%

See 2 more Smart Citations

Cetuximab Given Every 2 Weeks plus Irinotecan Is an Active and Safe Option for Previously Treated Patients with Metastatic Colorectal Cancer

et al. 2010

View full text Add to dashboard Cite

Background: We gathered data from multiple institutions on the cetuximab regimen of patients with metastatic colorectal cancer. Methods: 126 patients from 19 centers were included from July 2006 to July 2007 in this prospective non-controlled study. Irinotecan-refractory metastatic colorectal cancer patients with Karnofsky ≧70 received cetuximab 500 mg/m² every 2 weeks (q2w) in combination with irinotecan 180 mg/m² q2w until disease progression or unacceptable toxicity. The primary endpoint was the progression-free rate at 12 weeks. Results: Median age was 65 years; 65.9% male; colon/rectum 64.3/34.1%; Karnofsky status ≤80/≧90% in 45.3/54.7% of the patients. The progression-free rate was 42.7 (95% CI 32.8–52.6) and 22.4% (95% CI 14.2–30.7) at 12 and 24 weeks, respectively. The main grade 3 or 4 toxicities were: diarrhea 13.5% and acne-like rash 10.3%. No grade 3 or 4 infusional or allergic reactions were reported. Conclusions: The progression-free rates confirm that cetuximab q2w in combination with irinotecan is an option, and is as active and safe as the standard weekly regimen.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionsupporting

confidence: 87%

mentioning

confidence: 99%

See 1 more Smart Citation

Cetuximab Given Every 2 Weeks plus Irinotecan Is an Active and Safe Option for Previously Treated Patients with Metastatic Colorectal Cancer

et al. 2010

View full text Add to dashboard Cite

show abstract

“…These patients were unresectable after two or more lines of conventional treatment and prior to the initiation of the treatment with cetuximab. 13 The results from phase I study 14 and phase II study showed that cetuximab could be safely administered every second week. 15 …”

Section: Metastatic Colorectal Cancer (Crc)mentioning

confidence: 99%